

Faller, Robert B. - Medicaid

From: Bettie L. Black [bettie2330@cableone.net]
Sent: Friday, January 08, 2010 11:43 AM
To: Undisclosed-Recipient;;
Subject: Overactive Bladder Class and VESicare

8 January 2010

Tami Eide, Pharm.D.
Bob Faller, Pharm.D.

I am a urologist located in Idaho Falls. It has been brought to my attention that in the near future you will be reviewing the Idaho Medicaid Preferred Drug List.

I see many Medicaid patients diagnosed with overactive bladder. For their continued excellent health care with the use of VESicare for treatment, I would ask that you please retain this drug as "preferred" on your list.

Thank you for your consideration.

Sincerely,

Timothy O. Taylor, MD
2330 Coronado
Idaho Falls, ID 83404
208-552-1234



LYNN P. ESKELSON, M.D.
FAMILY PRACTICE



HOSPITAL: 44 North First East
Preston, Idaho 83263
Telephone: (208) 852-0137
Fax: (208) 852-3511
www.fcmc.org

OFFICE: Central Square Medical Plaza
47 North First East
Preston, Idaho 83263
Telephone: (208) 852-2900
Fax: (208) 852-3511

December 29, 2009

Idaho Medicaid P&T Committee
Attention: Bob Faller
3232 Elder Street
Boise, ID 83705

Mr. Faller:

I understand that at an upcoming meeting, your committee will be reviewing lipid medicines for inclusion in the Medicaid Formulary. I would request that you add TriLipix to the formulary. TriLipix has been a valuable addition to our treatment options for triglycerides and HDL, especially since it has an indication to be used with statins. Our Medicaid patients would benefit from having access to this medicine.

I make this request on my own behalf and have received no compensation or have no affiliation with any drug manufacturer.

Cordially,

Lynn Eskelson, M.D.

CARDIOLOGY
BOARD CERTIFIED

ANITA E. ROBINSON, M.D., F.A.C.C.

FELLOW
AMERICAN COLLEGE OF CARDIOLOGY

1607 LINCOLN WAY, SUITE 200
COEUR D'ALENE, ID 83814
208-765-4440 FAX 208-667-7062

December 21, 2009

TO: IDAHO MEDICAID

RE: NEBIVOLOL

TO WHOM IT MAY CONCERN:

It is my understanding that you are considering Nebivolol for approval on Medicaid. I have used Nebivolol in select patients. It is a unique beta-blocker with vasodilatory action that is not by alpha blockade. It is very useful in patients who need a beta-blocker, but have Raynaud's or have asthma. It is a beta-1-selective beta-blocker. There is a very extensive review in the Journal of the American College of Cardiology, October 13, 2009, Volume 54, Number 16, Pages 1491-1500.

Nebivolol is approved for treatment of hypertension in the United States. It has been used for over ten years in Europe for hypertension, as well as angina, dysrhythmias and left ventricular dysfunction.

Thank you for the consideration of the addition of Nebivolol to your formulary.

Sincerely,



Anita E. Robinson, M.D., F.A.C.C.

AER:dm